Skip to main content
. Author manuscript; available in PMC: 2015 Jul 28.
Published in final edited form as: J Cancer Ther. 2011 Mar 31;2(1):22–39. doi: 10.4236/jct.2011.21004

Figure 9.

Figure 9

Relative cytotoxic anti-neoplastic potency of selenium and celecoxib measured as a function of chemotherapeutic-resistant SKBr-3 mammary carcinoma survivability with and without epirubicin (10−7 M). Legend: (∎) selenium (methyl-seleninate) 30 μM, 40 μM, and 50 μM with and without the presence of epirubicin at 10−7 M fixed concentration; (∎) celecoxib at 30 μM, 40 μM, and 50 μM with and without the presence of epirubicin at 10−7 M fixed concentration. Monolayers of SKBr-3 mammary carcinoma were incubated with immunochemotherapeutics over a 72-hour period and cytotoxicity measured as a function of MTT cell vitality relative to matched negative reference controls.